Chinese company to use AI-powered chromosome testing to boost profits and fast-track IVF
China’s falling fertility rate sees spike in demand for assisted reproduction as biotech firm raises US$101 million from Hong Kong listing
“In China, many young people do not want to marry or have children, and by the time they decide to start a family, they need medical help to do so,” said Diagens’ founder and executive director Song Ning.
Song said it was a market with “enormous growth potential”.
Diagens, whose shares commenced trading on the local exchange on Monday, opened at HK$219, before retreating to HK$195 at 9.55am, up 97 per cent from its offer price of HK$99. They closed at HK$209.60.
“Our technological strength will help more patients combat the unknown territories of their diseases,” Song said before trading opened. “The Hong Kong listing marks a restart of Diagens’ efforts to scale new heights in medical science.”